PACAP-38
Pituitary Adenylate Cyclase-Activating Polypeptide 38
PACAP-38 is a 38-amino acid neuropeptide belonging to the secretin/glucagon/VIP superfamily, endogenously expressed throughout the nervous system, pituitary, adrenal glands, and gonads. It is primarily investigated in research contexts for its potent neuroprotective, anti-inflammatory, and neurotrophic properties, with emerging interest in stress response modulation, migraine pathophysiology, and potential neurodegenerative disease applications. PACAP-38 is the predominant endogenous form of PACAP and is approximately 1000-fold more potent than its truncated counterpart PACAP-27 at PAC1 receptors.
Mechanism of Action
PACAP-38 exerts its effects primarily through three G-protein coupled receptors: PAC1 (highly selective, Gs and Gq coupled), VPAC1, and VPAC2 (shared with VIP, Gs coupled), leading to robust activation of adenylate cyclase, elevation of intracellular cAMP, and downstream PKA and MAPK/ERK signaling cascades. At PAC1 receptors, it also activates phospholipase C, generating IP3 and DAG to mobilize intracellular calcium, producing pleiotropic effects including neuronal survival promotion, BDNF upregulation, inhibition of apoptotic pathways (Bcl-2 upregulation, caspase-3 inhibition), and potent modulation of hypothalamic-pituitary-adrenal axis activity. Additionally, PACAP-38 stimulates catecholamine release from the adrenal medulla and regulates circadian rhythm entrainment via retinohypothalamic tract signaling to the suprachiasmatic nucleus.
Evidence by Health Goal(18 goals)
Dosing Protocols
Morning administration preferred, given stimulatory and cortisol-modulating effects
Cycle: 4-6 weeks on, 4 weeks off
Subcutaneous injection is the most commonly used route in preclinical and early human research. Start at the low end (1 mcg/kg) to assess vasodilatory and flushing responses. Intravenous dosing (used in clinical migraine studies at 10 mcg over 20 minutes) produces significantly more pronounced side effects and is not recommended outside clinical settings. Dosing guidance extrapolated largely from animal studies and limited Phase I/II human trials.
Morning, on an empty stomach to optimize absorption
Cycle: 4 weeks on, 2-4 weeks off
Intranasal delivery offers a non-invasive route with potential direct nose-to-brain transport via olfactory and trigeminal pathways, bypassing the blood-brain barrier. Bioavailability is significantly lower than injection and highly variable. This route is experimental with minimal human pharmacokinetic data; dosing is largely speculative and derived from animal intranasal studies. Use of an appropriate mucosal penetration enhancer may be required.
Safety & Side Effects
PACAP-38 is an experimental research peptide with no approved therapeutic indications as of 2024; its safety profile in humans is derived primarily from small clinical studies (migraine provocation, Phase II trials) and extrapolation from extensive animal data, meaning long-term safety is unknown. Cardiovascular effects (hypotension, tachycardia, flushing) are consistently reported and represent the primary acute risk, while its potent neuroendocrine activity raises concerns about chronic HPA and autonomic dysregulation; individuals with migraine, cardiovascular disease, or psychiatric conditions should exercise particular caution.
Possible Side Effects
- !Facial flushing and cutaneous vasodilation (most common, dose-dependent, typically within minutes of administration)
- !Transient hypotension and dizziness due to potent vasodilatory effects
- !Headache and migraine-like episodes (PACAP-38 IV infusion is established as a migraine trigger in susceptible individuals)
- !Tachycardia and palpitations secondary to cardiovascular effects
- !Nausea and gastrointestinal discomfort, particularly with systemic administration
- !HPA axis dysregulation with prolonged use, potentially altering cortisol rhythms and stress reactivity
- !Local injection site reactions including erythema, swelling, and transient pain
- !Anxiety or heightened arousal due to catecholamine and CRF pathway stimulation
Interactions
- -May potentiate hypotensive effects of antihypertensives, vasodilators, and nitrates - use with extreme caution and monitor blood pressure closely
- -May enhance insulin secretion and risk of hypoglycemia when combined with insulin or sulfonylureas due to beta-cell PAC1/VPAC receptor stimulation
- -Potential additive stimulatory effects on HPA axis when combined with CRH, corticosteroids, or other stress-axis modulators, risking dysregulation of cortisol rhythms
- -Theoretical interaction with triptans and CGRP-targeting migraine therapies - PACAP-38 provokes migraine through distinct mechanisms and co-administration in migraine-prone individuals is inadvisable
- -May amplify effects of other cAMP-elevating compounds (e.g., forskolin, theophylline, PDE inhibitors) leading to excessive downstream signaling
Cost & Where to Buy
Research-grade PACAP-38 is available from peptide synthesis vendors at approximately $30-120 per 1 mg vial depending on purity (>98% HPLC) and supplier; at 2-3x weekly dosing of 200-300 mcg per injection, a month's supply requires roughly 2-4 mg of peptide. Costs are highly variable based on vendor, batch size, and purity grade. PACAP-38 is a custom-synthesized longer peptide (38 residues) and is generally more expensive per mg than shorter peptides. Not approved or commercially available as a pharmaceutical; sold strictly as a research chemical.
Search on Amazon